Please assess the completion status of the following clinical trial:

Trial Title: Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIb with documented malignant pleural effusion or stage IV~* Immunohistochemical evidence of EGFR expression on tumor tissue~* Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area~Exclusion Criteria:~* Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR-targeting therapy~* Previous chemotherapy for NSCLC~* Documented or symptomatic brain metastasis~* Superior vena cava syndrome contra-indicating hydration~* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab plus chemotherapy (Type: EXPERIMENTAL): cetuximab + cisplatin + vinorelbine
- Chemotherapy alone (Type: ACTIVE_COMPARATOR): cisplatin + vinorelbine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).